GSK (GSK) return on equity (ROE)
GSK earned a return on equity of 34.9% in fiscal 2025 (the year ended December 31, 2025). That is 16.1 percentage points higher than the 18.8% of fiscal 2024. Figures as of 17 Nov 2026, 21:32 UTC, from Yahoo Finance.
Key facts
- Return on equity, fiscal 2025
- 34.9%
- Change on fiscal 2024
- +16.1 pts
- Highest on record
- 141.1%fiscal 2022
- Lowest on record
- 18.8%fiscal 2024
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Figures, not advice.
GSK return on equity (ROE), in more detail
Across the 4 fiscal years on record (2022–2025), the highest was 141.1% in fiscal 2022 and the lowest 18.8% in fiscal 2024. The fiscal 2025 figure is higher than in 33% of the 3 earlier fiscal years on record, whose median is 36.9%.
Return on equity by fiscal year
GSK return on equity (ROE), year by year
| Fiscal year | Return on equity | Change | Year ended |
|---|---|---|---|
| 2025 | 34.9% | 16.1 pts up | |
| 2024 | 18.8% | 18.1 pts down | |
| 2023 | 36.9% | 104.2 pts down | |
| 2022 | 141.1% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
How to read it
It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.
Return on equity at health care companies of similar size
| Company | Return on equity | Fiscal year |
|---|---|---|
| Sanofi SNY | 10.9% | 2025 |
| Moderna MRNA | -32.6% | 2025 |
| CVS Health CVS | 2.4% | 2025 |
| HCA Healthcare HCA | 656.3% | 2020 |
| GSK GSK | 34.9% | 2025 |
| Regeneron Pharmaceuticals REGN | 14.4% | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
GSK, figure by figure
- GSK market cap
- GSK revenue
- GSK earnings
- GSK earnings per share (EPS)
- GSK P/E ratio
- GSK P/S ratio
- GSK P/B ratio
- GSK free cash flow
- GSK operating margin
- GSK dividend
- GSK shares outstanding
- GSK total debt
- GSK cash on hand
- GSK total assets
- GSK return on invested capital (ROIC)
GSK (GSK) overview: price, valuation and scorecardAll health care companies by market value
GSK return on equity (ROE): questions and answers
What is GSK's return on equity?
GSK earned a return on equity of 34.9% in fiscal 2025 (the year ended December 31, 2025). That is 16.1 percentage points higher than the 18.8% of fiscal 2024.
Is GSK's return on equity high or low compared with its own history?
The fiscal 2025 figure is higher than in 33% of the 3 earlier fiscal years on record, whose median is 36.9%.
What are the highest and lowest return on equity figures on record for GSK?
Across the 4 fiscal years on record (2022–2025), the highest was 141.1% in fiscal 2022 and the lowest 18.8% in fiscal 2024.
How is GSK's return on equity calculated?
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: return on equity (ROE)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “GSK (GSK) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/GSK/roe
Underlying data: Yahoo Finance.